Pharmaceutical Regulatory Affairs - Carlow
Special Features of this programme
The primary objective of this Masters is to enable learners to expand their job responsibilities and opportunities in new areas after completing the programme. It will also enable learners to create an excellent network within the pharmaceutical industry, both by meeting other regulatory professionals during the course and by interacting with industry experts while completing their dissertation research.
Subjects taught
What subjects will I study?
Lifecycle Management, Vigilance, Surveillance and Risk management
Pharmaceutical Technology Regulatory Affairs
Non Clinical and Clinical Evaluation of Pharmaceutical Technologies
Principles of Discovery of Medicines and Development Planning
Research Methods and Technical Report Writing
Special Populations and Biologicals and Advanced Therapies
Dissertation
Entry requirements
A second-class honours degree in science, engineering, quality, pharmaceutical or regulatory affairs or cognate areas. Those failing to meet the classification requirement may be eligible for entry to the Postgraduate Diploma.
Candidates with significant experience in: pharmaceutical operations, quality engineering, device design, mid to senior management in industry, other professionals who wish to upskill in the regulatory affairs environment, regulatory affairs personnel themselves who want to upskill (as determined by the Institute’s recognition of prior learning policy), in addition to an honours primary degree in another discipline area may also be considered for entry.
Duration
1 Year Full-time/2 Years Part-time
Post Course Info
Study & Career Opportunities
Opportunities for graduates from this programme include progression to Level 10 (PhD) programmes in related fields of study.
According to a report from the Forfás Expert Group on Future Skills Needs, Ireland is emerging as a leading location for biopharmaceuticals with a mix of start-ups, high growth SMEs and large multinationals located here.
Industry leaders including Pfizer, Eli Lilly, Sanofi, MSD (biologics based in Carlow) and Alkermes plc. have significant investment in Ireland which has facilitated rapid growth and development of the industry.
These coupled with a strong generics industry (Wockhardt, Clonmel Healthcare both based in the South-East) provide prospective employment opportunities for graduates and key engagement partners for the programme.
More than 85 pharmaceutical companies (including nine of the top 10) operate over 100 facilities in Ireland. The industry exports around $85 billion worth of products each year and is now one of the largest exporters of pharmaceuticals in the world. This programme is designed to meet the growing demand for scientists to service the current and emerging biotechnology-based industries in Ireland in particular, the South-East, Mid-East and Midlands.